Surabgene Lomparvovec

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

13 Countries

Phase III

Phase II

Phase III/IV

Phase III: 1 Phase II: 1 Phase III/IV: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Neovascular age-related macular degeneration 3

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 3

All trials

3 total

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Pending

2023-505750-17-00 Phase II 5 countries AbbVie Deutschland GmbH & Co. KG
Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting

2024-512298-28-00 Phase III/IV 13 countries AbbVie Deutschland GmbH & Co. KG
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended

2023-503666-23-00 Phase III 5 countries Abbvie Deutschland GmbH & Co. KG

Showing 1–3 of 3 trials

← All drugs A–Z